Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - ksilometazolinklorid - sprej za nos, otopina - 0,5 mg/ml - urbroj: jedan ml spreja za nos, otopine sadrži 0,5 mg ksilometazolinklorida; jedan potisak (70 µl) sadrži 0,035 mg ksilometazolinklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - ksilometazolinklorid - sprej za nos, otopina - 1 mg/ml - urbroj: jedan ml spreja za nos, otopine sadrži 1 mg ksilometazolinklorida; jedan potisak (140 µl) sadrži 0,140 mg ksilometazolinklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - ibuprofenum, pseudoephedrinum - filmom obložena tableta - 200 mg + 30 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg ibuprofena i 30 mg pseudoefedrinklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb - risperidonum - prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem - 37,5 mg - urbroj: 1 bočica (=98,4 mg mikrosfere) sadržava 37,5 mg risperidona

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - topiramat - filmom obložena tableta - 100 mg - urbroj: 1 topamax 100 mg filmom obložena tableta sadržava 100 mg topiramata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - topiramat - filmom obložena tableta - 200 mg - urbroj: 1 topamax 200 mg filmom obložena tableta sadržava 200 mg topiramata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - topiramat - filmom obložena tableta - 25 mg - urbroj: 1 topamax 25 mg filmom obložena tableta sadržava 25 mg topiramata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - topiramat - filmom obložena tableta - 50 mg - urbroj: 1 topamax 50 mg filmom obložena tableta sadržava 50 mg topiramata